New hope for babies with rare hormone disorder?
NCT ID NCT07187375
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 23 times
Summary
This study is testing an experimental drug called crinecerfont in 6 infants under 2 years old who have congenital adrenal hyperplasia (CAH), a condition where the body can't make certain hormones properly. The goal is to see how the drug moves through the body and if it is safe. All children must already be on stable hormone therapy to join.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL ADRENAL HYPERPLASIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Neurocrine Clinical Site
RECRUITINGBerlin, 13353, Germany
-
Neurocrine Clinical Site
RECRUITINGDüsseldorf, 40225, Germany
-
Neurocrine Clinical Site
RECRUITINGHeidelberg, 69120, Germany
Conditions
Explore the condition pages connected to this study.